Back

HUTCHMED starts Phase Ia trial of HMPL-A830 KRAS therapy conjugate

Verifying
  • HUTCHMED initiated the Phase Ia global trial of HMPL-A830 in advanced solid-tumor patients.
  • The first patient received HMPL-A830’s first dose in China on September 24, 2026.
  • HUTCHMED Limited leads global Phase I development under an agreement with a GSK plc subsidiary.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.